CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-26 | Konstantinov Konstantin Director | Grant or award · Stock Option (Right to Buy) | +2,498 | 2,498 | ||
| 2022-05-26 | DAWES KAREN A Director | Grant or award | +644 | 77,176 | ||
| 2022-05-26 | DAWES KAREN A Director | Grant or award · Stock Option (Right to Buy) | +1,565 | 1,565 | ||
| 2022-05-26 | BARTHELEMY NICOLAS Director | Grant or award | +534 | 2,081 | ||
| 2022-05-26 | BARTHELEMY NICOLAS Director | Grant or award · Stock Option (Right to Buy) | +1,298 | 1,298 | ||
| 2022-05-26 | MUIR GLENN P Director | Grant or award | +534 | 6,896 | ||
| 2022-05-26 | MUIR GLENN P Director | Grant or award · Stock Option (Right to Buy) | +1,298 | 1,298 | ||
| 2022-05-26 | EGLINTON MANNER CARRIE Director | Grant or award | +1,024 | 1,481 | ||
| 2022-05-26 | EGLINTON MANNER CARRIE Director | Grant or award · Stock Option (Right to Buy) | +2,488 | 2,488 | ||
| 2022-05-25 | DAWES KAREN A Director | Sale | −2,576 | $149.18 | $384K | 88,671 |
| 2022-05-25 | DAWES KAREN A Director | Sale | −7,677 | $150.19 | $1.2M | 80,994 |
| 2022-05-25 | DAWES KAREN A Director | Sale | −1,845 | $151.14 | $279K | 79,149 |
| 2022-05-25 | DAWES KAREN A Director | Sale | −1,875 | $152.14 | $285K | 77,274 |
| 2022-05-25 | DAWES KAREN A Director | Sale | −742 | $152.84 | $113K | 76,532 |
| 2022-05-13 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −712 | $150.40 | $107K | 20,110 |
| 2022-05-13 | Gebski Christine See Remarks | Shares withheld for taxes | −335 | $150.40 | $50K | 34,092 |
| 2022-05-13 | Snodgres Jon Chief Financial Officer | Shares withheld for taxes | −712 | $150.40 | $107K | 39,187 |
| 2022-04-01 | Bylund James Chief Operating Officer | Shares withheld for taxes | −335 | $188.02 | $63K | 9,733 |
| 2022-03-16 | EGLINTON MANNER CARRIE Director | Purchase | +625 | $175.02 | $109K | 2,106 |
| 2022-03-08 | Snodgres Jon Chief Financial Officer | Option exercise | +2,952 | $33.87 | $100K | 38,685 |
Page 20 of 23 · 455 trades